Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Recruiting 10Completed 3Active not recruiting 3Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 8OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Neurotoxicity Syndromes 1Lymphoma, Non-Hodgkin 1Hematologic Neoplasms 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × axicabtagene ciloleucel × Clear all
NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT05108805 2025-03-27

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Vanderbilt-Ingram Cancer Center

Phase 4 Completed
25 enrolled 17 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
22 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡